Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Synopsys outlines $9.56B–$9.66B revenue target for 2026 as Ansys integration advances

View original at seekingalpha.com
Synopsys outlines $9.56B–$9.66B revenue target for 2026 as Ansys integration advances Earnings Call Insights: Synopsys (SNPS) Q1 2026 MANAGEMENT VIEW * CEO Sassine Ghazi highlighted a strong start to Synopsys’ 40th anniversary year, emphasizing an expanded portfolio and leadership positions, stating, "In Q1, we achieve…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Reiterating full year revenue, non-GAAP operating margin and cash flow guidance while raising non-GAAP EPS guidance for the full year

    80% confidence
  • Confidence in IP business pickup is driven by the design starts and the breadth of the portfolio

    80% confidence
  • Feeling great about the progress being made on the roadmap

    80% confidence
  • Classic Synopsys was down slightly in China, whereas Ansys portfolio performed fairly well due to export restrictions and customer behavior shifts to domestic foundries

    80% confidence
  • There's a much bigger opportunity and growth opportunity for the interface IP, which is where investments will focus

    80% confidence
  • AI isn't disrupting our business. It's amplifying our strategic advantage.

    80% confidence
  • Q1 '26 marked a strong start to the year with revenue at the upper end of guided range, non-GAAP operating margin of 42.1% and non-GAAP EPS above guidance

    80% confidence
  • Synopsys won a marquee emulation win versus the incumbent at a leading AI HPC customer

    80% confidence
  • With muted growth in IP, we get muted operating margin; expectation is that once titles are on time, it's a very good business

    80% confidence
  • Synopsys has the right skills and is putting the right resources and priority to deliver on time and schedule for IP titles

    80% confidence
  • Backlog building and consumption is an ebb and flow; sitting at $11.3 billion of backlog feels great

    80% confidence
  • Ansys now supports more than 90% of the top 100 automotive suppliers

    80% confidence
  • Backlog ended at $11.3 billion, underscoring strong and resilient business model

    80% confidence
  • The first half of 2026 will deliver the first wave of joint Synopsys-Ansys solutions; monetization to start in FY 2027

    80% confidence
  • Hardware business had a record year last year and expectation is to continue delivering given demand and complexity

    80% confidence
  • AI agents for chip design cannot hallucinate and must be 100% accurate as you move through the workflow

    80% confidence
  • Q1 2026 achieved revenue at the high end of guidance and non-GAAP EPS exceeded guidance

    80% confidence
  • 2026 is the year Synopsys begins delivering on the technology promise of the Synopsys plus Ansys combination

    80% confidence
  • Advanced nodes saw 100% usage on critical tape-outs at 2-nanometer and below

    80% confidence
  • 2026 is a transitional year for Design IP segment, with focus on aligning the fastest-growing segments of the silicon market

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Synopsys outlines $9.56B–$9.66B revenue target for 2026 as Ansys integration advances — Source | Via News | ViaNews Market